M&A deals, company strategies, pipeline updates and more
Follow our coverage of the 2019 J.P. Morgan Healthcare Conference in San Francisco
Since GSK pulled LYMErix in 2002, there's been no FDA-approved Lyme shot, and Valneva's VLA15 is the only active clinical program.
After a horrible flu season last year, more people have gotten vaccinations so far this year, according to the CDC.
Merck & Co. struck a deal with Brazil's Butantan Institute to push ahead with their respective dengue development programs.
Here is some other vaccine news of note for the week.
Experts urged the U.S. to allow CDC staff to return to the field, though WHO's director-general insists financial and other support should suffice.
GlaxoSmithKline is working to boost its supply of shingles vaccine Shingrix, but in the meantime, a shortage will last until next year.
With the help of BioNTech and CEPI's $8.4 million, Imperial College London will work on a self-amplifying RNA vaccine platform.
As officials scramble to contain an Ebola outbreak in the Democratic Republic of Congo, the WHO is worried that Merck's vaccine stockpile won't last.
Based in Oxford and slated to open in 2022, the center will focus on creating rapid, cost-effective ways of developing and manufacturing vaccines.